TSC2 and neoplasm: Human hepatocellular carcinomas (HCCs) with inactive Tsc2 mutations exhibit more aggressive tumor behavior in patients, and Tsc2 mutation-bearing HCCs are more sensitive to rapamycin in patient-derived tumor xenograft models151.